請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/46295
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 蘇銘嘉(Ming-Jai Su),賴凌平 | |
dc.contributor.author | Wan-Hsuan Hsu | en |
dc.contributor.author | 許婉萱 | zh_TW |
dc.date.accessioned | 2021-06-15T05:02:10Z | - |
dc.date.available | 2020-12-31 | |
dc.date.copyright | 2010-09-13 | |
dc.date.issued | 2010 | |
dc.date.submitted | 2010-07-28 | |
dc.identifier.citation | Abbott RD, Donahue RP, Kannel WB, Wilson PW. The impact of diabetes on survival following myocardial infarction in men vs. women: the Framingham Study. The Journal of the American Medical Association. 1988; 260:3456-3460.
Aguilar D, Solomon SD, Kober L, Rouleau J-L, Skali H, McMurray JJV, Francis GS, Henis M, O’Connor CM, Diaz R, Belenkov YN, Varshavsky S, Leimberger JD, Velazquez EJ, Califf RM, Pfeffer MA. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction the valsartan in acute myocardial infarction (VALIANT) trial. Circulation. 2004; 110:1572-1578. An W, Yang J, Ao Y. Metallothionein mediates cardioprotection of isoliquiritigenin against ischemia-reperfusion through JAK2/STAT3 activation. Acta Pharmacologica Sinica. 2006; 27:1431-1437. Ananthakrishnan R, Hallam K, Li Q, Ramasamy R. JAK-STAT pathway in cardiac ischemic stress. Vascular Pharmacology. 2005; 43:353-356. Barry SP, Townsend PA, Latchman DS, Stephanou A. Role of the JAK-STAT pathway in myocardial injury. Trends in Molecular Medicine. 2006; 13:82-89. Bhamra GS, Hausenloy DJ, Davidson SM, Carr RD, Paiva M, Wynne AM, Mocaun MM, Yellon DM. Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Research in Cardiology. 2008; 103:274-284. Borutaite V, Jekabsone A, Mokuniene R, Brown GC. Inhibition of mitochondrial permeability transition prevents mitochondrial dysfunction, cytochrome c release and apoptosis induced by heart ischemia. Journal of Molecular and Cellular Cardiology. 2003; 35:357-66. Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? The Journal of Clinical Investigation. 1985; 76:1713-9. Buja LM. Myocardial ischemia and reperfusion injury. Cardiovascular Pathology. 2005; 14:170-175. Cerra FB, Lajos TZ, Montes M, Siegel JH. Hemorrhagic infarction: A reperfusion injury following prolonged myocardial ischemic anoxia. Surgery. 1975; 78:95-104. Garcia-Lafuente A, Guillamon E, Villares A, Rostagno MA, Martinez JA. Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular disease. Inflammation Research. 2009; 58:537-552. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion- a target for cardioprotection. Cardiovascular Research. 2004; 61:372-385. Hardie DG. Role of AMP-activated protein kinase in the metabolic syndrome and in heart disease. FEBS letters. 2008; 582:81-89. Hardie DG, Hawley SA, Scott JW. AMP-activated protein kinase- development of the energy sensor concept. The Journal of physiology. 2006; 574:7-15. Hausenloy DJ, Tsang A, Yellon DM. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trendsin Cardiovascular Medicine. 2005; 15:69-75. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signaling: taking a RISK for cardioprotection. Heart Failure Reviews. 2007; 12:217-234. Honda HM, Korge P, Weiss JN. Mitochondria and ischemia/ reperfusion injury. The New York Academy of Sciences. 2005; 1047:248-258. Hutchinson DS, Summers RJ, Bentsson T. Regulation of AMP-activated protein kinase activity by G-protein coupled receptors: potential utility in treatment of diabetes and heart disease. Pharmacology & Therapeutics. 2008; 119:291-310. Hwang J-T, Kwon DY, Yoon SH. AMP-activated protein kinase: a potential target for the diseases prevention by natural occurring polyphenols. New Biotechnology. 2009; 26:17-21. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. The Journal of the American Medical Association. 2002; 287:360-372. Javadov S, Karmazyn M. Mitochondrial permeability transition pore opening as an endopoint to initiate cell death and as a putative target for cardioprotection. Cellular Physiology and Biochemistry. 2007; 20:1-22 Jennings RB, Sommers HM, Smyth GA, Flack HA, Linn H. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Archives of Pathology & Laboratory Medicine. 1960; 70:68-78. Jeong JJ, Ha YM, Jin YC, Lee EJ, Kim JS, Kim HJ, Seo HG, Lee JH, Kang SS, Kim YS, Chang KC. Rutin from Lonicera japonica inhibits myocardial ischemia/ reperfusion- induced apoptosis in vivo and protects H9c2 cells against hydrogen peroxide-mediated injury via ERK1/2 and PI3K/Akt signals in vitro. Food and Chemical Toxicology. 2009; 47:1569-1576. Juhaszova M, Zorov DB, Yaniv Y, Nuss HB, Wang S, Sollott SJ. Role of glycogen synthase kinase-3 in cardioprotection. Circulation Research. 2009; 104:1240-1252. Kang S, Yang Y. Coronary microvascular reperfusion injury and no-reflow in acute myocardial infarction. Clinical & Investigative Medicine. 2007; 30:E133-E145. Kassab E, McFarlane SI, Sowers JR. Vascular complications in diabetes and their prevention. Vascular Medicine. 2001; 6:249-255. Kim AS, Miller EJ, Young LH. AMP-activated protein kinase: a core signaling pathway in the heart. Acta Physiologica. 2009; 196:37-53. Knnel WB, McGee DL. Diabetes and cardiovascular disease: the Farmingham Study. The Journal of the American Medical Association. 1979; 241:2035-2038. Kulasa KM, Henry RR. Pharmacotherapy of hyperglycemia. Expert Opinion on Pharmacotherapy. 2009; 10:2415-2432. Lalu MM, Wang W, Schulz R. Peroxynitrite in myocardial ischemia-reperfusion injury. Heart Failure Reviews. 2002; 7:359-69. Miura T, Miki T. GSK-3β, a therapeutic target for cardiomyocyte protection. Circulation Journal. 2009; 73:1184-1192. Miyamoto S, Murphy AN, Browmn JH. Akt mediated mitochondrial protection in the heart: metabolic and survival pathways to the rescue. Journal of Bioenergetics and Biomembranes. 2009; 41: 169-180. Modriansky M, Gabrielova E. Uncouple my heart: the benefits of inefficiency. Journal of Bioenergetics and Biomembranes. 2009; 41:133-136. Moens AL, Claeys MJ, Timmermans JP, Vrints CJ. Myocardial ischemia/reperfusion- injury, a clinical view on a complex pathophysiological process. International Journal of Cardiology. 2005; 100:179-90. Monassier JP. Reperfusion injury in acute myocardial infarction. From bench to cath lab. Part 1: Basic considerations. Archives of Cardiovascular Disease. 2008; 101:491-500. Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiological Reviews. 2008; 88:581-609 Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986; 74:1124-1136. Perez-Vizcaino F, Duarte J, Jimenez R, Santos-Buelga C, Osuna A. Antipertensive effects of the falconoid quercetin. Pharmacological Reports. 2009; 61:67-75. Philippe J, Raccah D. Treating type 2 diabetes: how safe are current therapeutic agents? International Journal of Clinical Practice. 2009; 63:321-332. Powers SK, Murlasits Z, Wu M, Kavazis AN. Ischemia- Reperfusion- induced cardiac injury: a brief review. Medicine and Science in Sports and Exercise. 2007; 39:1529-1536 Prasad A, Stone GW, Holmes DR, Gersh B. Reperfusion injury, microvascular dysfunction, and cardioprotection: the “dark side” of reperfusion. Circulation. 2009; 120:2105-2122. Raza JA, Reinhart RA, Movahed A. Ischemic heart disease in women and the role of hormone therapy. International Journal of cardiology. 2004; 96:2-19. Sajan MP, Bandyopadhyay G, Miura A, Standaert ML, Nimal S, Longnus SL, Obberghen EV, Hainault EVOI, Foufelle F, Kahn R, Braun U, Leitges M, Farese RV. AICAR and metformin, but not exercise, increase muscle glucose transport through AMPK-, ERK-, and PDK1-dependent activation of atypical PKC. American Journal of Physiology – Endocrinology and Metabolism. 2010; 298:179-192. Scarpello JHB, Howlett HCS. Metformin therapy and clinical uses. Diabetes and Vascular Disease Research. 2008; 5:157-167. Schimmack G, DeFronza RA, Musi N. AMP-activated protein kinase: role in metabolism and therapeutic implications. Diabetes, Obesity and Metabolism. 2006; 8:591-602. Serafini M, Peluso I, Raguzzini A. Flavonoids as anti-inflammatory agents. Proceedings of the Nutrition Society. 2010; 3:1-6. Shao Z-H, Wojcik KR, Dossumbekova A, Hsu C, Mehendale SR, Li C-Q, Qin Y, Sharp WW, Chang W-T, Hamann KJ, Yuan C-S, Hoek TLV. Grape seed proanthocyanidins protect cardiomyocytes from ischemia and reperfusion injury via Akt-NOS signaling. Journal of Cellular Biochemistry. 2009; 107:697-705. Solaini G, Harris DA. Biochemical dysfunction in heart mitochondria exposed to ischaemia and reperfusion. Biochemical Journal. 2005; 390:377-394. Stoclet J-C, Chataigneau T, Ndiaye M, Oak MH, Bedoui JE, Chataigneau M, Schini-Kerth VB. Vascular protection by dietary polyphenols. European Journal of Pharmacology. 2004; 500:299-313. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Yellon. Postconditioning: A form of “modified reperfusion” protects the myocardium by activating the phosphatidylinositol 3-kinase-akt pathway. Circulation Research. 2004; 95:230-232. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovascular Research. 2004; 61:481-497. Whelan RS, Kaplinskiy V, Kitsis RN. Cell death in the pathogenesis of heart disease: mechanisms and significance. Annual Review Physiology. 2010; 72:19-44. Wong AKF, Howie J, Petrie JR, Lang CC. AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease. Clinical Science. 2009; 116:607-620. Yellon DM, D. Sc., Hausenloy DJ. Myocardial reperfusion injury. The New England Journal of Medicine. 2007; 357:1121-35. Zhao Z-Q, Corvera JS, Halkos ME, Kerendi F, Wang N-P, Guyton RA, Vinten-Johansen J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. American Journal of Physiology – Heart and Circulatory Physiolgy. 2003; 285:H579-H588. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/46295 | - |
dc.description.abstract | 背景:組織缺血後再灌流引起的損傷在臨床上很常見,病人施行心血管手術或器官移植後,或於心肌梗塞、冠狀動脈阻塞及缺血性中風的情況下,都可能引起再灌流損傷,影響預後。希望能研究利用自然界豐富的植物成分及抗糖尿病用藥對心臟的保護作用。本篇主要研究類黃酮成分RS47、642D及降血糖藥物metformin對於H9c2細胞缺氧再灌流造成的損傷,是否具保護作用,並探討其可能的機轉。
方法及結果:H9c2細胞為胚胎大鼠心臟細胞株,利用缺氧艙及無糖無血清的培養液造成6小時的缺氧,之後再灌流12小時。實驗分成不加藥組 (vehicle) 及加藥組 (RS47、642D、metformin) ,加藥組為缺氧前1小時將不同濃度的藥物加入培養液,作用1小時,實驗結束後利用MTT assay觀察細胞存活比率,並利用西方點墨法、PI3K-Akt inhibitor、AMPK inhibitor、ERK inhibitor及LDH assay,更進一步探討RS47、642D及metformin的作用機轉。從MTT assay的結果發現,加藥組顯著的增加了細胞存活率。而西方點墨法觀察藥物相關蛋白質表現量,發現RS47組、642D組及metformin組Akt、AMPK及ERK的磷酸化皆顯著增加;另外,p38、Bax的磷酸化顯著減少,GSK-3β的磷酸化顯著增加。之後利用PI3K-Akt inhibitor LY294002、AMPK inhibitor Compound C及ERK inhibitor PD98059,發現LY294002及Compound C可以抑制三種藥物的細胞存活率增加,PD98059可以抑制metformin的細胞存活率增加。接著利用LDH觀察細胞壞死,其結果與MTT assay符合。 結論:RS47、642D及metformin對於H9c2細胞缺氧再灌流損傷具有保護作用,RS47及642D可能的機轉是透過Akt和AMPK活化,而metformin的機轉可能是經由活化Akt、ERK及AMPK,以減少細胞凋亡及壞死途徑,降低細胞再灌流損傷引起的細胞死亡。 | zh_TW |
dc.description.abstract | Background:Reperfusion injury during recovery phase of tissue ischemia is important in many clinical situations such as cardiac transplantation, myocardial infarction and stroke, which influence outcome of the patients. We are interested in whether the natural ingredients and anti-diabetic medicines are protective against ischemic heart disease. The aim of the present study was to investigate the protective effects of flavonoids and metformin on H9c2 hypoxia-reoxygenation induced injury.
Methods and Results:We used rat heart-derived cell line, H9c2, for the experiments. Cells were placed in hypoxia chamber with no glucose no serum medium to induce hypoxia 6 hr, then changed to normoxic condition for 12 hours. Cells were divided into vehicle and drug group. In drug group, RS47, 642D and metformin were added in the medium 1 hr before hypoxia. MTT assay was used to show cell viability of hypoxia reoxygenation. Western blot、PI3K-Akt inhibitor LY294002、ERK inhibitor PD98059 and AMPK inhibitor Compound C were also used in the present study. In MTT assay, cell viability was significantly increased in the drug group when compared to sham group. Western blot analysis revealed that p-Akt、p-AMPK and p-ERK were increased in the drug group, p-p38 and Bax were decreased, and p-GSK-3β was elevated. The use of Compound C significantly inhibited the protective effect of RS47、642D and metformin. We also measured LDH release, the results matched MTT assay. Conclusion:RS47, 642D and metformin signigicantly increased the cell viability in H9c2 cell hypoxia reoxygenation injury, and this was attributed to a decrease of cell apoptosis and necrosis. The decreased reperfusion injury was related to activation of Akt、AMPK and ERK. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T05:02:10Z (GMT). No. of bitstreams: 1 ntu-99-R97443020-1.pdf: 5684130 bytes, checksum: 556252a9234a2d65c81dad753f77a87d (MD5) Previous issue date: 2010 | en |
dc.description.tableofcontents | 口試委員審定書……………………………………………………………i
致謝………………………………………………………………………...ii 縮寫表……………………………………………………………………..iii 中文摘要…………………………………………………………………..iv 英文摘要…………………………………………………………………..vi 第一章 緒論…………………………………………………………….....1 第二章 實驗材料與方法………………………………………………...29 第三章 實驗結果…………………………………………………...……38 第四章 討論……………………………………………………..……….59 第五章 結論與展望……………………………………………………...63 參考文獻………………………………………………………………….64 | |
dc.language.iso | zh-TW | |
dc.title | RS47, 642D和Metformin對H9c2細胞缺氧再灌流之保護作用 | zh_TW |
dc.title | The protective effect of RS47, 642D and metformin on H9c2 cell hypoxia reoxygenation | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 顏茂雄(Mao-Hsiung Yen),林正一(cheng-I Lin),蔡佳醍(Chia-Ti Tsai) | |
dc.subject.keyword | 缺氧再灌流,metformin,Akt,AMPK, | zh_TW |
dc.subject.keyword | Hypoxia-reoxygenation,metformin,Akt,AMPK, | en |
dc.relation.page | 71 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2010-07-28 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-99-1.pdf 目前未授權公開取用 | 5.55 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。